Esomeprazole MUPS 40 mg tablets and esomeprazole MUPS 40 mg tablets encapsulated in hard gelatine are bioequivalent

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 1, 2005, Pages 51-56

  Talpes, S ^a   Knoerzer, D ^b   Huber, R ^b   Pfaffenberger, Bernd ^b  

^a ALTANA Pharma AG ^*  (Romania)

^b ALTANA PHARMA AG   (Germany)

Author keywords

Bioequivalence; Crossover studies; Pharmacokinetics; Proton pump inhibitor; Therapeutic equivalence

Indexed keywords

ESOMEPRAZOLE; GELATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; HEART VENTRICLE ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NONPARAMETRIC TEST; NORMAL HUMAN; PARAMETRIC TEST; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TABLET FORMULATION;

EID: 12344307627     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP43051     Document Type: Article

References (17)

1. Agentia Nationala a Medicamentului Romania 1999 Buletin informativ. An I, Nr 1, trim I
2. Andersson T, Magner DJ, Patel JB, Rogers P, Levine JG 2000 Esomeprazole open capsule mixed with apple-sauce is bioequivalent to the intact capsule when administered to healthy volunteers. Am J Gastroenterol 95 (Abstract 128): 2448
3. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L 2001 Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 40: 411-426
4. Declaration of Helsinki as revised in Somerset West, Republic of South Africa 1996
5. Diletti E, Hauschke D, Steinijans VW 1991 Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29: 1-8
6. Directive 95/46/EC of the European Parliament and of the Council on the protection of individuals with regard to the processing of personal data and on the free movement of such data 1995. Official Joumal 281: 31-50
7. EMEA 2001 Guideline CPMP/EWP/QWP/1401/98: Note for Guidance on the investigation of bioavailability and bioequivalence 1-18
8. Hassan-Alin M, Andersson T, Bredberg E, Rohss K 2000 Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 56: 665-670
9. Johnson DA, Benjamin SB, Vakil NB, Goldstein JL, Lamet M, Whipple J, Damico D, Hamelin B 2001 Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 96: 27-34
10. Maton PN, Vakil NB, Levine JG, Hwang C, Skammer W, Lundborg P 2001 Esomeprazole Study Investigators. Safety and efficacy of long-term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 24: 625-635
11. Sauter R, Steinijans VW, Diletti E, Bohm A, Schulz HU 1992 Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 30: 233-256
12. Schaltenbrand R, Huber R, Cotoraci CA, Mascher H, Potthast H, Hole U 2001 Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule. Int J Clin Pharmacol Ther 39: 453-459
13. Scholten T, Gatz G, Hole U 2003 Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 18: 587-594
14. Simon B, Muller P, Pascu O, Gatz G, Sander P, Huber R, Mascher H 2003 Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a cross-over study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 15: 791-799
15. Spencer CM, Faulds D 2000 Esomeprazole. Drugs 60: 321-329
16. Tolman KG, Chandramouli J, Fang JC 2000 Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother 1: 1171-1194
17. Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, D'Amico D, Hamelin B 2001 The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 15: 927-935